Published in J Clin Microbiol on October 05, 2011
Evaluation of the chromogenic agar chromID C. difficile. J Clin Microbiol (2012) 1.11
Toxin synthesis by Clostridium difficile is regulated through quorum signaling. MBio (2015) 0.91
Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol (2014) 0.81
Bile salt inhibition of host cell damage by Clostridium difficile toxins. PLoS One (2013) 0.78
Evaluation of a chromogenic culture medium for the detection of Clostridium difficile. Yonsei Med J (2014) 0.76
Accessory Gene Regulator-1 Locus Is Essential for Virulence and Pathogenesis of Clostridium difficile. MBio (2016) 0.76
A Decade of Development of Chromogenic Culture Media for Clinical Microbiology in an Era of Molecular Diagnostics. Clin Microbiol Rev (2017) 0.75
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med (2005) 16.59
Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol (1979) 12.54
Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet (2005) 12.54
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Clinical practice. Antibiotic-associated diarrhea. N Engl J Med (2002) 7.13
Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis (2001) 6.92
Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature (1995) 6.08
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
The role of toxin A and toxin B in Clostridium difficile infection. Nature (2010) 5.32
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis (2007) 4.61
The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol (2007) 4.09
Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis (2008) 3.88
Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis (2008) 3.49
The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem (1995) 3.02
Large clostridial cytotoxins--a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol (1996) 2.85
Hospitals battling outbreaks of C. difficile. CMAJ (2004) 2.76
Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol (2006) 2.72
Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med (2001) 2.72
Purification and characterization of Clostridium difficile toxin. Infect Immun (1979) 2.71
Repression of Clostridium difficile toxin gene expression by CodY. Mol Microbiol (2007) 2.28
Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem (1997) 2.25
Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol (2003) 2.24
Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01
Large clostridial cytotoxins. Rev Physiol Biochem Pharmacol (2004) 2.00
Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile. J Clin Microbiol (2000) 1.91
The toxigenic element of Clostridium difficile strain VPI 10463. Microb Pathog (1995) 1.89
Localization of the glucosyltransferase activity of Clostridium difficile toxin B to the N-terminal part of the holotoxin. J Biol Chem (1997) 1.83
Clostridium difficile PCR ribotype 078: an emerging strain in humans and in pigs? J Clin Microbiol (2008) 1.66
Growth of Clostridium difficile and production of toxins A and B in complex and defined media. J Med Microbiol (1986) 1.62
Clostridium difficile-associated diarrhoea. Intern Med J (2007) 1.54
Laboratory diagnosis of Clostridium difficile disease. Clin Microbiol Infect (2001) 1.43
Clostridium difficile toxins: more than mere inhibitors of Rho proteins. Int J Biochem Cell Biol (2008) 1.27
Involvement of Ras-related Rho proteins in the mechanisms of action of Clostridium difficile toxin A and toxin B. Infect Immun (1995) 1.26
Evaluation of two rapid assays for detection of Clostridium difficile toxin A in stool specimens. J Clin Microbiol (1999) 1.23
Positive regulation of Clostridium difficile toxins. Infect Immun (1997) 1.17
Effects of Clostridium difficile toxins on epithelial cell barrier. Ann N Y Acad Sci (2000) 1.14
An unusual case of 'uncompetitive activation' by ascorbic acid: purification and kinetic properties of a myrosinase from Raphanus sativus seedlings. Biochem J (1999) 1.14
Single toxin detection is inadequate to diagnose Clostridium difficile diarrhea in pediatric patients. Gastroenterology (1998) 1.14
Transcriptional analysis of the toxigenic element of Clostridium difficile. Microb Pathog (1997) 1.13
Bacteriophage-mediated toxin gene regulation in Clostridium difficile. J Virol (2009) 1.09
Toxin production by Clostridium difficile in a defined medium with limited amino acids. J Med Microbiol (1994) 1.00
Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes. Shock (2000) 0.93
Cytotoxic effects of the Clostridium difficile toxins. Curr Top Microbiol Immunol (2000) 0.86
Harnessing the glucosyltransferase activities of Clostridium difficile for functional studies of toxins A and B. J Clin Microbiol (2011) 0.82
Methods for isolation of anaerobes in the clinical laboratory. Am J Med Technol (1975) 0.81
Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet (2008) 2.79
Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis (2006) 2.35
Strongyloides hyperinfection syndrome: an emerging global infectious disease. Trans R Soc Trop Med Hyg (2008) 2.09
Escherichia coli Pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis (2010) 1.60
Exopolysaccharide biosynthesis genes required for social motility in Myxococcus xanthus. Mol Microbiol (2005) 1.52
Vitamin A supplementation has divergent effects on norovirus infections and clinical symptoms among Mexican children. J Infect Dis (2007) 1.50
A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg (2006) 1.46
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother (2009) 1.20
Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter species. J Clin Microbiol (2010) 1.12
A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis (2010) 1.11
Characterization of a Myxococcus xanthus mutant that is defective for adventurous motility and social motility. Microbiology (2004) 1.10
Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol (2009) 1.10
Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents (2009) 0.97
Native valve endocarditis caused by Corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy? Antimicrob Agents Chemother (2012) 0.97
Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol (2008) 0.97
Guideline for the management of acute diarrhea in adults. J Gastroenterol Hepatol (2002) 0.97
PCR-based assay using occult blood detection cards for detection of diarrheagenic Escherichia coli in specimens from U.S. travelers to Mexico with acute diarrhea. J Clin Microbiol (2008) 0.95
Natural competence is a major mechanism for horizontal DNA transfer in the oral pathogen Porphyromonas gingivalis. MBio (2012) 0.93
Enteroaggregative Escherichia coli (EAEC): a cause of acute and persistent diarrhea of worldwide importance. J Infect Dis (2010) 0.93
Vitamin A supplementation reduces the monocyte chemoattractant protein-1 intestinal immune response of Mexican children. J Nutr (2006) 0.92
Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis (2012) 0.91
Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease. Inflamm Bowel Dis (2013) 0.90
Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother (2012) 0.90
Enteroaggregative Escherichia coli: an emerging pathogen in children. Semin Pediatr Infect Dis (2004) 0.87
A nosocomial outbreak of norovirus infection masquerading as clostridium difficile infection. Clin Infect Dis (2009) 0.87
New Developments in Traveler's Diarrhea. Gastroenterol Hepatol (N Y) (2011) 0.86
Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs (2010) 0.82
Harnessing the glucosyltransferase activities of Clostridium difficile for functional studies of toxins A and B. J Clin Microbiol (2011) 0.82
Epidemiology of travelers' diarrhea in Thailand. J Travel Med (2009) 0.82
The mechanistic basis of Myxococcus xanthus rippling behavior and its physiological role during predation. PLoS Comput Biol (2012) 0.82
Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother (2013) 0.82
Biochemical and genetic diversity of enterotoxigenic Escherichia coli associated with diarrhea in United States students in Cuernavaca and Guadalajara, Mexico, 2004-2007. J Infect Dis (2010) 0.82
A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers' diarrhea in Mexico during the dry season. J Travel Med (2011) 0.82
Enterococcus faecalis pCF10-encoded surface proteins PrgA, PrgB (aggregation substance) and PrgC contribute to plasmid transfer, biofilm formation and virulence. Mol Microbiol (2014) 0.80
Peripartum Clostridium difficile infection: case series and review of the literature. Am J Obstet Gynecol (2008) 0.79
Epidemiology of Clostridium difficile-associated diarrhea in a Peruvian tertiary care hospital. Am J Trop Med Hyg (2007) 0.79
Association of virulence factor-positive and -negative enteroaggregative Escherichia coli and occurrence of clinical illness in travelers from the United States to Mexico. Am J Trop Med Hyg (2003) 0.79
The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea. Ther Clin Risk Manag (2009) 0.79
Bile salt inhibition of host cell damage by Clostridium difficile toxins. PLoS One (2013) 0.78
Coliform contamination of vegetables obtained from popular restaurants in Guadalajara, Mexico, and Houston, Texas. Clin Infect Dis (2008) 0.78
Risk factors associated with diarrhea among international visitors to Cuzco, Peru. Am J Trop Med Hyg (2006) 0.78
Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother (2006) 0.78
Clostridium difficile infection: an emerging epidemic with more questions than answers. Future Microbiol (2010) 0.78
Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis. PLoS One (2013) 0.77
Advances in the treatment of travelers' diarrhea. Curr Gastroenterol Rep (2011) 0.77
Flat-panel versus 64-channel computed tomography for in vivo quantitative characterization of aortic atherosclerotic plaques. Int J Cardiol (2010) 0.75
An expert panel report of a proposed scientific model demonstrating the effectiveness of antibacterial handwash products. Am J Infect Control (2012) 0.75